Orgenesis Inc (NASDAQ:ORGS) said Monday that it plans to build an advanced production site in Belgium to help its subsidiary MaSTherCell Global manufacture commercially approved cell and gene therapy products.
The company signed a lease agreement for a 61,354 square foot space in a building located within Gosselies Biopark, in Belgium.
The new commercial facility, expected to be up-and-running by early-2021 will triple MaSTherCell Global’s capacity. The facility will include industry 4.0 precepts such as “software integration, intelligent equipment and integrated processes” which will provide cost-effective manufacturing solutions for cell and gene therapy customers.
Once the new commercial facility is operational, the current facility, also located within the Gosselies Biopark biotech cluster, will shift its focus to industrial manufacturing process development and early to mid-stage, clinically-focused cell and gene therapy products.
“We are excited to launch this new facility, which will significantly enhance our capacity to meet growing demand,” said Orgenesis CEO Vered Caplan in a statement. “This new facility will provide our customers unparalleled manufacturing capabilities and a strong competitive advantage. We believe this facility, in addition to our current global capabilities, will also help patients by providing greater access to life saving therapies.”
MaSTherCell Global is a leading cell and gene therapy global contract development and manufacturing organization, or CDMO.
“As a leading CDMO, MaSTherCell is working hard to address the lack of commercial manufacturing capacity, especially in Europe,” said Dr Denis Bedoret, president at MaSTherCell Global. “With this facility, we aim to be the first CDMO in Europe to have a dedicated area for large-scale commercial manufacturing.”
The new production facility will create local employment.
“It will create several hundred jobs and allow us to tap into local Belgian expertise to train our teams within the heart of Europe, in support of our international recruitment goals,” said Eric Mathieu, chief operating officer of MaSTherCell’s Belgium operations.
Contact Uttara Choudhury at [email protected]